
SIDP Advocacy Agenda

March 17, 2021

SIDP is committed to promoting appropriate use of antimicrobials, novel anti-infectives and vaccines (henceforth “antimicrobials”), through efforts that prioritize patient safety and well-being:

- *The SIDP Policy and Government Affairs Committee (PGA) focuses efforts on legislative and regulatory matters related to infectious diseases therapeutics and antimicrobial use and resistance.*
- *The SIDP Public Outreach Committee develops partnerships, activities, and programs that educate the general public on the safe and effective use of antimicrobials and pharmacists’ roles in antimicrobial stewardship.*
- *The SIDP DEI Task Force is committed to creating and sustaining an inclusive and welcoming society and improving the representation of minorities in our membership, leadership, and profession.*

SIDP advocates to government and private entities on key issues and educates the public, together with strategic partners, to enact positive change.

The following are advocacy priorities for SIDP:

1. Optimizing patient outcomes through the optimal use of antimicrobials, novel anti-infectives and vaccines (henceforth “antimicrobials”), including but not limited to:
 - a. Antimicrobial development, distribution, reimbursement, and clinical use
 - b. The intersection of antimicrobial use and public health
 - c. The intersection of antimicrobial use and patient safety
 - d. Antimicrobial use for therapeutic and non-therapeutic purposes in animal husbandry and agriculture
 - e. Funding for research and policy that support optimization of antimicrobial use outcomes including disparities in clinical applications, antimicrobial resistance and stewardship
2. Antimicrobial resistance (AMR) and patient safety:
 - a. AMR in hospitals, long-term care facilities, the ambulatory setting, animal husbandry and food supply chains
 - b. Funding for research and policy that support a comprehensive understanding of AMR and its impact on human and non-human health, including disparities in antimicrobial use, AMR and stewardship

3. Education of patients and healthcare professionals regarding the safe and effective use of antimicrobials, including but not limited to:
 - a. Partnering with external stakeholders to educate patients and healthcare professionals on matters related to antimicrobial use and outcomes, AMR, and infectious diseases prevention
 - b. Prioritizing education on disparities in antimicrobial use, antimicrobial stewardship, vaccines, and other infectious diseases therapeutics in minoritized communities
 - c. Prioritizing education on the role of the and value of infectious diseases pharmacists
 - d. Prioritizing education of patients
 - e. Prioritizing education of pharmacists practicing in non-infectious diseases areas of care
 - f. Prioritizing education of pharmacy trainees
4. The role of pharmacists as essential health care and public health providers in the fight against infectious diseases and AMR, including but not limited to:
 - a. Maintaining and advancing the role of pharmacists as practice leaders in established areas of antimicrobial stewardship and infectious diseases therapeutics
 - b. Maintaining and advancing the role of pharmacists as immunizers
 - c. Supporting and advancing the role of pharmacists as practice leaders in growing areas of antimicrobial stewardship and infectious diseases pharmacotherapy (e.g. long-term care, outpatient parenteral antimicrobial therapy, etc.)
 - d. Developing and supporting policies and programs directed at the development of infectious diseases pharmacists from minority backgrounds
 - e. Educating external stakeholders on the role and value of infectious diseases pharmacists